Weifa
Weifa AS [1] is a Norwegian pharmaceutical company specializing in pharmaceuticals and fine chemicals for world markets.
Weifa is one of the world’s largest producers of Metformin hydrochloride and a leading producer of alkaloid opiates. Production facilities follow GMP standards.
Therapeutic areas
Weifa focuses on three therapeutic areas:
- Pain management
- Diabetes management
- Food supplements
Development
With a total of over 250 employees, Weifa is today generating an annual turnover of approximately €40 million (35% of the turnover is achieved internationally). Weifa bases its development on 3 criteria:
- International expansion
- Expertise in pharmaceuticals and fine chemicals
- Partnership agreements
Norway
Weifa has market leadership in pain management products for the Norwegian market, with a portfolio of branded products that includes established brand names such as the Ibux tablets, Paracet tablets and Paralgin Forte tablets. Branded products accounts for approximately 70% of net sales.
Export
Weifa’s leading export markets are Germany and United Kingdom. Besides these two essential export markets, Weifa has a long-standing presence in all the main countries of the European Union, in Eastern Europe, in Africa, in North America, in South America and in Asia.